Pulmonary sarcoidosis: an update

References

• Rybicki BA, Major M, Popovich J Jr, et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145(3):234–241.
   PubMed Web of Science ®Google Scholar
• Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med. 1997;336(17):1224.
   PubMed Web of Science ®Google Scholar
• Newman LS, Rose CS, Bresnitz EA, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170:1324–1330.
   PubMed Web of Science ®Google Scholar
• Müller-Quernheim J, Schurmann M, Hofmann S, et al. Genetics of sarcoidosis. Clin Chest Med. 2008;29:391–414.
   PubMed Web of Science ®Google Scholar
• Gerke AK, Hunninghake G. The immunology of sarcoidosis. Clin Chest Med. 2008 Sep;29(3):379–90, vii. DOI:10.1016/j.ccm.2008.03.014
   PubMed Web of Science ®Google Scholar
• Spagnolo P, Sato H, Grutters JC, et al. Analysis of BTNL2 genetic polymorphisms in British and Dutch patients with sarcoidosis. Tissue Antigens. 2007;70:219–227.
   PubMedGoogle Scholar
• Spagnolo P, Sato H, Grunewald J, et al. A common haplotype of the C-C chemokine receptor 2 gene and HLA-DRB1*0301 are independent genetic risk factors for Lofgren’s syndrome. J Intern Med. 2008;264:433–441.
   PubMed Web of Science ®Google Scholar
• Grunewald J, Brynedal B, Darlington P, et al. Different HLA-DRB1 allele distributions in distinct clinical subgroups of sarcoidosis patients. Respir Res. 2010;11:25.
   PubMed Web of Science ®Google Scholar
• Sato H, Grutters JC, Pantelidis P, et al. HLA- DQB1*0201: a marker for good prognosis in British and Dutch patients with sarcoidosis. Am J Respir Cell Mol Biol. 2002;27:406–412.
   PubMed Web of Science ®Google Scholar
• Sato H, Woodhead FA, Ahmad T, et al. Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups. Hum Mol Genet. 2010;19:4100–4111.
   PubMed Web of Science ®Google Scholar
• Wennerstrom A, Pietinalho A, Vauhkonen H, et al. HLA-DRB1 allele frequencies and C4 copy number variation in Finnish sarcoidosis patients and associations with disease prognosis. Hum Immunol. 2012;73(1):93–100.
   PubMed Web of Science ®Google Scholar
• Rossman MD, Thompson B, Frederick M, et al. HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet. 2003;73(4):720–735.
   PubMed Web of Science ®Google Scholar
• Grunewald J, Idali F, Kockum I, et al. Major histocompatibility complex class II transactivator gene polymorphism: associations with Lo ̈ fgren’s syndrome. Tissue Antigens. 2010;76:96–101.
   PubMedGoogle Scholar
• Iannuzzi MC, Maliarik MJ, Poisson LM, et al. Sarcoidosis susceptibility and resistance HLA- DQB1 alleles in African Americans. Am J Respir Crit Care Med. 2003;167:1225–1231.
   PubMed Web of Science ®Google Scholar
• van den Berg-Loonen EM, Voorter CEM, Drent M. Strong association of severe pulmonary sarcoid- osis with HLA DQB1*0602. Hum Immunol. 2004;65:826–835.
   PubMed Web of Science ®Google Scholar
• Ziegenhagen MW, Benner UK, Zissel G, et al. Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med. 1997;156:1586–1592.
   PubMed Web of Science ®Google Scholar
• Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994;331:1286–1292.
   PubMed Web of Science ®Google Scholar
• Moses HL, Yang EY, Pietenpol JA. TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell. 1990;63:245–247.
   PubMed Web of Science ®Google Scholar
• Salez F, Gosset P, Copin MC, et al. Transforming growth factor-beta1 in sarcoidosis. Eur Respir J. 1998;12:913–919.
   PubMed Web of Science ®Google Scholar
• Schurmann M, Reichel P, Muller-Myhsok B, et al. Results from a genome-wide search for predispos- ing genes in sarcoidosis. Am J Respir Crit Care Med. 2001;164:840–846.
   PubMed Web of Science ®Google Scholar
• Valentonyte R, Hampe J, Huse K, et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet. 2005;37:357–364.
   PubMed Web of Science ®Google Scholar
• Nguyen T, Liu XK, Zhang Y, et al. BTNL2, a butyrophilin-like molecule that functions to inhibit T cell activation. J Immunol. 2006;176:7354–7360.
   PubMed Web of Science ®Google Scholar
• Hofmann S, Franke A, Fischer A, et al. Genome- wide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis. Nat Genet. 2008;40:1103–1106.
   PubMed Web of Science ®Google Scholar
• Mrazek F, Stahelova A, Kriegova E, et al. Functional variant ANXA11 R230C: true marker of protection and candidate disease modifier in sarcoidosis. Genes Immun. 2011;12:490–494.
   PubMed Web of Science ®Google Scholar
• Song Z, Marzilli L, Greenlee BM, et al. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med. 2005;201:755–767.
   PubMed Web of Science ®Google Scholar
• Dubaniewicz A, Dubaniewicz-Wybieralska M, Sternau A, et al. Mycobacterium tuberculosis complex and mycobacterial heat shock proteins in lymph node tissue from patients with pulmonary sarcoidosis. J Clin Microbiol. 2006;44:3448–3451.
   PubMed Web of Science ®Google Scholar
• Carlisle J, Evans W, Hajizadeh R, et al. Multiple Mycobacterium antigens induce interferon-gamma production from sarcoidosis peripheral blood mono- nuclear cells. Clin Exp Immunol. 2007;150:460–468.
   PubMed Web of Science ®Google Scholar
• Drake WP, Dhason MS, Nadaf M, et al. Cellular recognition of Mycobacterium tuberculosis ESAT-6 and KatG peptides in systemic sarcoidosis. Infect Immun. 2007;75:527–530.
   PubMed Web of Science ®Google Scholar
• Allen S, Evans W, Carlisle J, et al. Superoxide dis- mutase a antigens derived from molecular analysis of sarcoidosis granulomas elicit systemic Th-1 immune responses. Respir Res. 2008;9:36.
   PubMed Web of Science ®Google Scholar
• Chen ES, Wahlstrom J, Song Z, et al. T-cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis. J Immunol. 2008;181:8784–8796.
   PubMed Web of Science ®Google Scholar
• Oswald-Richter KA, Culver DA, Hawkins C, et al. Cellular responses to mycobacterial antigens are present in bronchoalveolar lavage fluid used in the diagnosis of sarcoidosis. Infect Immun. 2009;77:3740–3748.
   PubMed Web of Science ®Google Scholar
• Hajizadeh R, Sato H, Carlisle J, et al. Mycobacterium tuberculosis antigen 85A induces Th-1 immune responses in systemic sarcoidosis. J Clin Immunol. 2007;27:445–454.
   PubMed Web of Science ®Google Scholar
• Moller DR. Potential etiologic agents in sarcoidosis. Proc Am Thorac Soc. 2007;4:465–468.
   PubMedGoogle Scholar
• Myers JL, Tazelaar HD. Challenges in pulmonary fibrosis: 6–Problematic granulomatous lung disease. Thorax. 2008;63:78–84.
   PubMed Web of Science ®Google Scholar
• Soler P, Basset F, Bernaudin JF, et al. Morphology and distribution of the cells of a sarcoid granuloma: ultrastructural study of serial sections. Ann N Y Acad Sci. 1976;278:147–160.
   PubMed Web of Science ®Google Scholar
• Silverstein E, Pertschuk LP, Friedland J. Immunofluorescent localization of angiotensin converting enzyme in epithelioid and giant cells of sarcoidosis granulomas. Proc Natl Acad Sci U S A. 1979;76:6646–6648.
   PubMed Web of Science ®Google Scholar
• Okabe T, Ishizuka S, Fujisawa M, et al. Sarcoid granulomas metabolize 25-hydroxyvitamin D3 in vitro. Biochem Biophys Res Commun. 1984;123:822–830.
   PubMed Web of Science ®Google Scholar
• Chapman JT, Mehta AC. Bronchoscopy in sarcoidosis: diagnostic and therapeutic interventions. Curr Opin Pulm Med. 2003;9:402–407.
   PubMed Web of Science ®Google Scholar
• Takemura T, Matsui Y, Saiki S, et al. Pulmonary vascular involvement in sarcoidosis: a report of 40 autopsy cases. Hum Pathol. 1992;23:1216–1223.
   PubMed Web of Science ®Google Scholar
• Corte TJ, Wells AU, Nicholson AG, et al. Pulmonary hypertension in sarcoidosis: a review. Respirology. 2011;16:69–77.
   PubMed Web of Science ®Google Scholar
• Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax. 2006;61:68–74.
   PubMed Web of Science ®Google Scholar
• Scadding JG. Prognosis of intrathoracic sarcoidosis in England. BMJ. 1961;2:1165–1172.
   PubMed Web of Science ®Google Scholar
• Nunes H, Uzunhan Y, Gille T, et al. Imaging of sarcoidosis of the airways and lung parenchyma and correlation with lung function. Eur Respir. 2012;40:750–765.
   PubMed Web of Science ®Google Scholar
• Keijsers RG, Veltkamp M, Grutters JC. Chest imaging. Clin Chest Med. 2015;36(4):603–619.
   PubMed Web of Science ®Google Scholar
• Braun JJ, Kessler R, Constantinesco A, et al. 18F-FDGPET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging. 2008;35:1537–:1543.
   Web of Science ®Google Scholar
• Teirstein AS, Machac J, Almeida O, et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest. 2007;132:1949–1953.
   PubMed Web of Science ®Google Scholar
• Keijsers RG, van den Heuvel DA, Grutters JC. Imaging the inflammatory activity of sarcoidosis. Eur Respir J. 2013;41:743–751.
   PubMed Web of Science ®Google Scholar
• Keijsers RG, Verzijlbergen JF, van Diepen DM, et al. 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis. 2008;25:143–149.
   PubMed Web of Science ®Google Scholar
• Milman N, Graudal N, Loft A, et al. Effect of the TNFalpha inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET. Clin Respir J. 2012;6:238–247.
   PubMed Web of Science ®Google Scholar
• Mostard RL, Verschakelen JA, van Kroonenburgh MJ, et al. Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis. Respir Med. 2013;107:439–447.
   PubMed Web of Science ®Google Scholar
• Lazar CA, Culver DA. Treatment of sarcoidosis. Semin Respir Crit Care Med. 2010;31:501–518.
   PubMed Web of Science ®Google Scholar
• Teirstein AS, Morgenthau AS. ‘End-stage’ pulmonary fibrosis in sarcoidosis. Mt Sinai J Med. 2009;76:30–36.
   PubMedGoogle Scholar
• Keijsers RG, Verzijlbergen EJ, van den Bosch JM, et al. 18F-FDG PET as a predictor of pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28:123–129.
   PubMed Web of Science ®Google Scholar
• Keijsers RG, Grutters JC, Thomeer M, et al. Imaging the inflammatory activity of sarcoidosis: sensitivity and inter observer agreement of (67)Ga imaging and (18)F-FDG PET. Q J Nucl Med Mol Imaging. 2011 Feb;55(1):66–71.
   PubMed Web of Science ®Google Scholar
• Nagai S, Izumi T. Bronchoalveolar lavage still useful in diagnosing sarcoidosis? Clin Chest Med. 1997;18:787–797.
   PubMed Web of Science ®Google Scholar
• Navani N, Booth HL, Kocjan G, et al. Combination of endobronchial ultrasound-guided transbronchial needle aspiration with standard bronchoscopic techniques for the diagnosis of stage I and stage II pulmonary sarcoidosis. Respirology. 2011;16:467–472.
   PubMed Web of Science ®Google Scholar
• Oki M, Saka H, Kitagawa C, et al. Prospective study of endobronchial & ultrasound-guided transbronchial needle aspiration of lymph nodes versus transbronchial lung biopsy of lung tissue for diagnosis of sarcoidosis. J Thorac Cardiovasc Surg. 2012;143:1324–1329.
   PubMed Web of Science ®Google Scholar
• Tremblay A, Stather DR, Maceachern P, et al. A randomized controlled trial of standard vs endobronchial ultrasonography-guided transbronchial needle aspiration in patients with suspected sarcoidosis. Chest. 2009;136:340–346.
   PubMed Web of Science ®Google Scholar
• Studdy PR, James DG. The specificity and sensitivity of serum angiotensin converting enzyme in sarcoidosis and other diseases: experience in twelve centers in six different countries. Sarcoidosis. 1981;4:332–344.
   Google Scholar
• Lieberman J, Nosal A, Schlessner A, et al. Serum angiotensin- converting enzyme for diagnosis and therapeutic evaluation of sarcoidosis. Am Rev Respir Dis. 1979;120:329–335.
   PubMed Web of Science ®Google Scholar
• Ainslie GM, Benatar SR. Serum angiotensin converting enzyme in sarcoidosis: sensitivity and specificity in diagnosis: correlations with disease activity, duration, extra-thoracic involvement, radiographic type and therapy. Quarterly J Med. 1985;55:253–270.
   PubMedGoogle Scholar
• Ungprasert P, Carmona EM, Crowson CS, et al. Diagnostic utility of angiotensin-converting enzyme in sarcoidosis: a population-based study. Lung. 2016 Feb;194(1):91–95.
   PubMed Web of Science ®Google Scholar
• Studdy PR, Bird R. Serum angiotensin converting enzyme in sarcoidosis–its value in present clinical practice. Ann Clin Biochem. 1989 Jan;26(Pt 1):13–18.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Medical therapy of sarcoidosis. Semin Respir Crit Care Med. 2014;35(3):391–406.
   PubMed Web of Science ®Google Scholar
• Hunninghake GW, Costabel U, Ando M, et al. ATS/
ERS/WASOG statement on sarcoidosis. American thoracic society/European respiratory society/World association of sarcoidosis and other granulomatous disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(2):149–173.
   PubMed Web of Science ®Google Scholar
• Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med. 2010;104(5):717–723.
   PubMed Web of Science ®Google Scholar
• McKinzie BP, Bullington WM, Mazur JE, et al. Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations. Am J Med Sci. 2010;339(1):1–4.
   PubMed Web of Science ®Google Scholar
• Goldstein DS, Williams MH. Rate of improvement of pulmonary function in sarcoidosis during treatment with corticosteroids. Thorax. 1986;41(6):473–474.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Iannuzzi MC, Lower EE, et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19(3):198–204.
   PubMed Web of Science ®Google Scholar
• Gottlieb JE, Israel HL, Steiner RM, et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest. 1997;111(3):623–631.
   PubMed Web of Science ®Google Scholar
• Israel HL, Fouts DW, Beggs RA. A controlled trial of prednisone treatment of sarcoidosis. Am Rev Re- spir Dis. 1973;107(4):609–614.
   PubMed Web of Science ®Google Scholar
• Johns CJ, Schonfeld SA, Scott PP, et al. Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroid therapy. Outcome and complications. Ann N Y Acad Sci. 1986;465:702–712.
   PubMed Web of Science ®Google Scholar
• Hunninghake GW, Gilbert S, Pueringer R, et al. Outcome of the treatment for sarcoidosis. Am J Re- spir Crit Care Med. 1994;149(4 Pt 1):893–898.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17(1):60–66.
   PubMed Web of Science ®Google Scholar
• Cremers JP, Drent M, Bast A, et al. Multinational evidence-based world association of sarcoidosis and Other granulomatous disorders recommendations for the use of methotrexate in 
sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med. 2013;19(5):545–561.
   PubMed Web of Science ®Google Scholar
• Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med. 1995;155(8):846–851.
   PubMedGoogle Scholar
• Baughman RP, Lower EE. A clinical approach to the use of methotrexate for sarcoidosis. Thorax. 1999;54(8):742–746.
   PubMed Web of Science ®Google Scholar
• Zisman DA, McCune WJ, Tino G, et al. Drug- induced pneumonitis: the role of methotrexate-. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18(3):243–252.
   PubMed Web of Science ®Google Scholar
• Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. Ann Intern Med. 1994;121:833–841.
   PubMed Web of Science ®Google Scholar
• Vorselaars AD, Wuyts WA, Vorselaars VM, et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest. 2013 Sep;144(3):805–812.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21:43–48.
   PubMed Web of Science ®Google Scholar
• Sahoo DH, Bandyopadhyay D, Xu M, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J. 2011;38(5):1145–1150.
   PubMed Web of Science ®Google Scholar
• Hamzeh N, Voelker A, Forsse ́n A, et al. Efficacy of mycophenolate mofetil in sarcoidosis. Respir Med. 2014;108(11):1663–1669.
   PubMed Web of Science ®Google Scholar
• Brill AK, Ott SR, Geiser T. Effect and safety of mycophenolate mofetil in chronic pulmonary sarcoid- osis: a retrospective study. Respiration. 2012;86(5):376–383.
   PubMed Web of Science ®Google Scholar
• Drent M, Cremers JP, Jansen TL, et al. Practical eminence and experience-based recommendations for use of TNF-alpha inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(2):91–107.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795–802.
   PubMed Web of Science ®Google Scholar
• Judson MA, Baughman RP, Costabel U, et al. The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial. Respir Med. 2014;108(1):189–194.
   PubMed Web of Science ®Google Scholar
• Panselinas E, Rodgers JK, Judson MA. Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respirology. 2009;14(4):522–528.
   PubMed Web of Science ®Google Scholar
• Crommelin HA, van der Burg LM, Vorselaars AD, et al. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab. Respir Med. 2016;115:72–77.
   PubMed Web of Science ®Google Scholar
• Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update – a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006;25:745–755.
   PubMed Web of Science ®Google Scholar
• Trulock EP, Edwards LB, Taylor DO, et al. Registry of the International Society for Heart and Lung Transplantation (twenty-second official adult lung and heart-lung transplant report—2005). J Heart Lung Transplant. 2005;24:956–967.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Orens JB, Deeb M, et al. Recurrence of sarcoidosis following bilateral allogeneic lung transplantation. Chest. 1994;106:1597–1599.
   PubMed Web of Science ®Google Scholar
• Arcasoy SM, Christie JD, Pochettino A, et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest. 2001;120:873–880.
   PubMed Web of Science ®Google Scholar
• Shorr AF, Davies DB, Nathan SD. Outcomes for patients with sarcoidosis awaiting lung transplantation. Chest. 2002;122:233–238.
   PubMed Web of Science ®Google Scholar
• Shorr AF, Helman DL, Davies DB, et al. Pulmonary hypertension in advanced sarcoidosis (epidemiology and clinical characteristics). Eur Respir J. 2005;25:783–788.
   PubMed Web of Science ®Google Scholar
• Kouranos V, Hansell DM, Sharma R, et al. Advances in imaging of cardiopulmonary involvement in sarcoidosis. Curr Opin Pulm Med. 2015;21(5):538–545.
   PubMed Web of Science ®Google Scholar